



Oncomine™ Childhood Cancer Research Assay

203 Gene list

| Comprehensive Mutation Coverage (82) | | | Full Exon Coverage (44) | | CNV (24) | Fusion and Expression (97) | | | |
|--------------------------------------|----------|------------------|-------------------------|---------|----------|----------------------------|--------|---------|---------------------------------|
| ABL1 | FASLG | NCOR2 | APC | PTEN | ALK | ABL1 | JAK2 | NTRK1 | TAL1 |
| ABL2 | FBXW7 | NOTCH1 | ARID1A | RB1 | BRAF | ABL2 | KAT6A | NTRK2 | TCF3 |
| ALK | FGFR2 | NPM1 | ARID1B | RUNX1 | CCND1 | ALK | KMT2A | NTRK3 | TFE3 |
| ACVR1 | FGFR3 | NRAS | ATRX | SMARCA4 | CDK4 | BCL11B | KMT2B | NUP214 | TP63 |
| AKT1 | FLT3 | NT5C2 | CDKN2A | SMARCB1 | CDK6 | BCOR | KMT2C | NUP98 | TSLP |
| ASXL1 | GATA2 | PAX5 | CDKN2B | SOCS2 | EGFR | BCR | KMT2D | NUTM1 | TSPAN4 |
| ASXL2 | GNA11 | PDGFRA | CEBPA | SUFU | ERBB2 | BRAF | LMO2 | NUTM2B | UBTF |
| BRAF | GNAQ | PDGFRB | CHD7 | SUZ12 | ERBB3 | CAMTA1 | MAML2 | PAX3 | USP6 |
| CALR | H3F3A | PIK3CA PIK3R1 | CRLF1 | TCF3 | FGFR1 | CCND1 | MAN2B1 | PAX5 | WHSC1 |
| CBL | HDAC9 | | DDX3X | TET2 | FGFR2 | CIC | MECOM | PAX7 | YAP1 |
| CCND3 | HIST1H3B | PPM1D | DICER1 | TP53 | FGFR3 | CREBBP | MEF2B | PDGFB | ZMYND11 |
| CCRS5 | HRAS | PTPN11 | EBF1 | TSC1 | FGFR4 | CRLF2 | MET | PDGFRA | ZNF384 |
| CDK4 | IDH1 | RAF1 | EED | TSC2 | GLI1 | CSF1R | MKL1 | PDGFRB | |
| CIC | IDH2 | RET | FAS | WHSC1 | GLI2 | DUSP22 | MLLT10 | PLAG1 | |
| CREBBP | IL7R | RHOA | GATA1 | WT1 | IGF1R | EGFR | MN1 | RAF1 | |
| CRLF2 | JAK1 | SETBP1 | GATA3 | XIAP | KIT | ETV6 | MYB | RANBP17 | Gene Expression |
| CSF1R | JAK2 | SETD2 | GNA13 | | KRAS | EWSR1 | MYBL1 | RARA | BCL2 |
| CSF3R | JAK3 | SH2B3 | ID3 | | MDM2 | FGFR1 | MYH11 | RECK | BCL6 |
| CTNNB1 | KDM4C | SH2D1A | IKZF1 | | MDM4 | FGFR2 | MYH9 | RELA | FGFR1 |
| DAXX | KDR | SMO | KDM6A | | MET | FGFR3 | NCOA2 | RET | FGFR4 |
| DNMT3A | KIT | STAT3 | KMT2D | | MYC | FLT3 | NCOR1 | ROS1 | IGF1R |
| EGFR | KRAS | STAT5B | MYOD1 | | MYCN | FOSB | NOTCH1 | RUNX1 | MET |
| EP300 | MAP2K1 | TERT | NF1 | | PDGFRA | FUS | NOTCH2 | SS18 | MYCN |
| ERBB2 | MAP2K2 | TPMT | NF2 | | PIK3CA | GLI1 | NOTCH4 | SSBP2 | MYC |
| ERBB3 | MET | USP7 | PHF6 | | | GLIS2 | NPM1 | STAG2 | TOP2A |
| ERBB4 | MPL | ZMYM3 | PRPS1 | | | HMGA2 | NR4A3 | STAT6 | |
| ESR1 | MSH6 | | PSMB5 | | | | | | |
| EZH2 | MTOR | | PTCH1 | | | | | | |

Contact us to learn how Biodesix can support your program: bizdev@biodesix.com

About Biodesix

Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ and EarlyCDT Lung® nodule tests, evaluate the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.